Boehringer Ingelheim struck an agreement with the U.S. administration to join the TrumpRx.gov direct‑purchase platform and pledged $10 billion of investment into U.S. research, development and manufacturing through 2028. As part of the deal the company will participate in discounted medicine offerings and receive exemptions from potential Section 232 tariffs, according to company statements. Jean‑Michel Boers, Boehringer’s U.S. CEO, framed the arrangement as a combined effort to lower patient costs while expanding domestic manufacturing capacity. The pact adds to a string of voluntary pricing agreements between large drugmakers and the administration, creating new commercial and policy dynamics for market access and supply‑chain planning.